Floatz logo

FILGRASTIM

Antiphospholipid Syndrome

Johns Hopkins Universityprotein_peptideN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Antiphospholipid Syndrome cohort.

Asset / SponsorPhaseRating
WARFARIN
Seoul National University Hospital
Phase 4BB
Rivaroxaban
University College, London
Phase 2B
Bcma-Cd19 Ccar T Cells
Peking University People's Hospital
Phase 2CCC
hbi0101 cart
Polina Stepensky
Phase 1CC
Cyclophosphamide
Johns Hopkins University
N/AD

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →